EARLY-HF: Detecting EARLY Heart Failure in Greater Manchester

Sponsor
Manchester University NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05955456
Collaborator
(none)
600
1
84
7.1

Study Details

Study Description

Brief Summary

Heart failure represents a growing public health problem within the UK and particularly within the North West of England. A major challenge is that heart failure is currently diagnosed too late.

The researchers have previously developed a risk calculator that accurately identifies individuals at risk of heart failure admission or death before they have developed heart failure.

Most risk calculators are never implemented into clinical practice. The researchers will l perform a pilot study to evaluate the risk calculator within primary care in Greater Manchester.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

The researchers have previously developed and externally validated a novel multimodal risk calculator that accurately identifies individuals at-risk of heart failure admission or death before they have developed heart failure. This risk calculator includes key co-morbidities, circulating biomarkers and cardiac magnetic resonance imaging (CMR) measurements of cardiac structure and function. It identifies those individuals at highest risk of developing heart failure and therefore those who may most benefit from targeted cardiometabolic therapeutics in the future.

The researchers will l perform a pilot study to evaluate the risk calculator within primary care in Greater Manchester. A qualitative and quantitative assessment of risk calculator uptake will be performed within local GP practices and primary care populations. The research team will determine how effectively they can recruit participants from socioeconomically deprived and ethnically diverse backgrounds. A preliminary analysis will be performed to determine risk calculator accuracy within a prospective primary care cohort, and dynamically refine the model aiming to improve performance. The study will also involve conducting an initial cost effectiveness analysis to determine the real-world economic impact of model implementation.

Study Design

Study Type:
Observational
Anticipated Enrollment :
600 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Detecting EARLY Heart Failure in Greater Manchester (EARLY-HF)
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2030
Anticipated Study Completion Date :
Sep 1, 2030

Arms and Interventions

Arm Intervention/Treatment
Participants in primary care with risk factors for heart failure

Other: No intervention
No intervention is applied to participants. The risk calculator score is not released to the participants or care providers. Participants are followed up for risk calculator accuracy and recalibration.

Outcome Measures

Primary Outcome Measures

  1. Preliminary measures of risk calculator validation and accuracy in Greater Manchester [5 years]

    Risk calculator will predict incident heart failure, first heart failure hospitalisation, cardiovascular death and all cause death

Secondary Outcome Measures

  1. Qualitative measures of primary care uptake and engagement [5 years]

    Number of participant identification sites, methods of participant identification, proportion of eligible participants contacted and recruited

  2. Proportion of participants recruited from socioeconomically deprived and ethnically diverse backgrounds [5 years]

    Ability to recruit participants from socioeconomically deprived and ethnically diverse backgrounds within Greater Manchester

  3. Measures of prognostic model calibration and discrimination in a primary care population [5 years]

    Examples include calibration slope, intercept and Harrell's C statistic

  4. Measures of prognostic model optimisation and accuracy with iterative variable inclusion or exclusion [5 years]

    Assess variable inclusion and exclusion using stepwise model selection and Wald statistic

  5. Causal statistical analysis to determine effect of hypothetical interventions [5 years]

    Mediation analysis to determine causative effects of hypothetical interventions

  6. Measures of cost effectiveness of the model in Greater Manchester [5 years]

    Examples include decision curve analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Written informed consent

  • Aged 50 and over

  • Two or more of the following conditions: type 2 diabetes, chronic obstructive pulmonary disease, ischaemic heart disease, atrial fibrillation, hypertension, chronic kidney disease stage 3, body mass index ≥ 30 kg/m2

Exclusion Criteria:
  • Established diagnosis of one or more of the following: heart failure, cardiomyopathy, moderate or severe valvular heart disease, congenital heart disease, heart transplant, idiopathic, heritable or drug-induced pulmonary arterial hypertension, any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.

  • Contraindication to cardiovascular magnetic resonance (CMR) scanning, including pacemaker, defibrillator, intraocular metal, intracranial aneurysm clips, severe claustrophobia, estimated glomerular filtration rate < 30 ml/min/1.73m2, previous severe allergic reaction or anaphylaxis to gadolinium-based contrast agent, pregnancy or breastfeeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Manchester University NHS Foundation Trust Manchester Greater Manchester United Kingdom m13 9wl

Sponsors and Collaborators

  • Manchester University NHS Foundation Trust

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Manchester University NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT05955456
Other Study ID Numbers:
  • B01899
First Posted:
Jul 21, 2023
Last Update Posted:
Jul 21, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2023